Axillary Dissection May Be Unnecessary for Many Breast Cancer Patients

Publication
Article
OncologyONCOLOGY Vol 13 No 10
Volume 13
Issue 10

A new decision-making model developed by Dr.Giovanni Parmigiani and colleagues at Duke University has shown that the routine use of axillary lymph node dissection may not be necessary for many breast cancer patients. Recently, the use of

A new decision-making model developed by Dr.Giovanni Parmigiani and colleagues at Duke University has shown that the routine use of axillary lymph node dissection may not be necessary for many breast cancer patients. Recently, the use of axillary dissection has been questioned because lymph node status may not alter adjuvant therapy and because the survival benefit resulting from a change in adjuvant therapy would be small.

Only a Select Group of Patients May Benefit

The decision-making model was developed to quantify the survival benefits of axillary lymph node dissection in breast cancer patients receiving breast-conserving therapy. According to the model, axillary dissection only provides a small survival benefit in this population and is of greatest benefit to estrogen receptor positive women with small primary tumors who might not be eligible for adjuvant chemotherapy because their lymph nodes are negative. The model suggests that routine use of axillary lymph node dissection should be reassessed, and may be necessary only in select groups of patients.

Axillary lymph node dissection can cause numbness, swelling, and a decreased range of motion of the shoulder. Because of these side effects, sentinel node biopsy is currently being examined as a less invasive alternative.

Future studies will explore the use of the decision model as a counseling tool to help physicians and patients make better informed decisions regarding axillary lymph node dissection.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content